Response to pazopanib‐based combination regimen in a case of FGFR3 amplified gastric adenocarcinoma

Response to pazopanib‐based combination regimen in a case of FGFR3 amplified gastric adenocarcinoma

Abstract Angiogenesis inhibitors (AGI) are not presently used for the treatment of gastric cancers. This report demonstrates that angiogenesis inhibitor can be safely and effectively used in combination with cytotoxic anti‐cancer agents for treatment of Gastric cancers.

Guardado en:
Detalles Bibliográficos
Autores principales: Sewanti Limaye, Darshana Patil, Dadasaheb Akolkar, Navin Srivastava, Revati Patil, Sachin Apurwa, Sanket Patil, Jinumary John, Rahul Gosavi, Prabhu Nesargikar, Prashant Kumar, Vineet Datta, Chirantan Bose, Zarrine Raazi, Ajay Srinivasan, Rajan Datar
Formato: article
Lenguaje:EN
Publicado: Wiley 2021
Materias:
combination regimen
encyclopedic tumor analysis
gastric adenocarcinoma
pazopanib
personalized cancer treatment
precision oncology
Medicine
R
Medicine (General)
R5-920
Acceso en línea:https://doaj.org/article/65674c3e054d4917ac8f5a42efa27c35
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!

Internet

https://doaj.org/article/65674c3e054d4917ac8f5a42efa27c35

Ejemplares similares